Your browser is no longer supported. Please, upgrade your browser.
MRNA Moderna, Inc. daily Stock Chart
Moderna, Inc.
Index- P/E- EPS (ttm)-0.92 Insider Own6.90% Shs Outstand314.49M Perf Week-1.03%
Market Cap5.13B Forward P/E- EPS next Y-1.36 Insider Trans- Shs Float233.67M Perf Month-4.06%
Income-299.20M PEG- EPS next Q-0.36 Inst Own23.40% Short Float2.77% Perf Quarter-
Sales191.60M P/S26.77 EPS this Y-17.20% Inst Trans- Short Ratio3.40 Perf Half Y-
Book/sh-11.41 P/B- EPS next Y13.90% ROA- Target Price24.71 Perf Year-
Cash/sh3.41 P/C4.78 EPS next 5Y16.80% ROE- 52W Range13.03 - 22.75 Perf YTD6.81%
Dividend- P/FCF- EPS past 5Y- ROI50.30% 52W High-28.31% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low25.17% ATR1.11
Employees700 Current Ratio6.00 Sales Q/Q-41.50% Oper. Margin- RSI (14)- Volatility3.21% 6.91%
OptionableYes Debt/Eq- EPS Q/Q45.20% Profit Margin- Rel Volume0.16 Prev Close16.26
ShortableYes LT Debt/Eq- EarningsJan 14 AMC Payout- Avg Volume1.90M Price16.31
Recom1.80 SMA203.50% SMA50-0.67% SMA200-0.67% Volume315,678 Change0.31%
Jan-14-19 08:00AM  Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences ACCESSWIRE
Jan-09-19 04:05PM  Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019
12:13PM  Moderna Soars After Update of Its Pipeline Programs
10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
Jan-08-19 04:29PM  This New Biotech Stock Is Popping Will It Reclaim Its IPO Price? Investor's Business Daily
03:07PM  Moderna announces plans to bring three new drugs to clinic American City Business Journals
11:07AM  Moderna Shares Jump on Positive Cancer-Treatment Progress
08:48AM  Moderna's stock jumps after progress report on cancer treatments MarketWatch
08:45AM  Moderna CEO discusses company innovation following IPO CNBC Videos
08:30AM  Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives Business Wire
Jan-07-19 04:53PM  Biotech's big conference living up to reputation with big deals, big costs American City Business Journals
Jan-03-19 02:37PM  Analysts Issue New Ratings on Large Health Care Stocks
Jan-02-19 04:30PM  Morgan Stanley: Moderna Has Significant Competitive Advantage Benzinga
04:27PM  Could This New Biotech IPO Could Score Big With A Cancer Vaccine? Investor's Business Daily
04:15PM  Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference Business Wire
Dec-31-18 09:49AM  Moderna Analysts Plan Reckoning After Valuation Declines Bloomberg +7.92%
Dec-27-18 11:47AM  Andreas Halvorsen Invests in Biotech Company Moderna +8.36%
10:22AM  10 Hot Companies Going Public in 2019 InvestorPlace
Dec-21-18 05:20PM  Gossamer Bio files for IPO MarketWatch -6.65%
03:15PM  Alector, Gossamer chase Moderna with biotechnology IPOs-sources Reuters
Dec-18-18 12:41PM  IPO activity next year could dampen if markets do not rebound- report Reuters
Moderna, Inc. develops medicines based on messenger RNA (mRNA). Its pipeline includes development candidates for mRNA-based vaccines and therapies for use in various therapeutic areas comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.